Literature DB >> 16352616

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

Margaret A Knowles1.   

Abstract

Cancer of the bladder shows divergent clinical behaviour following diagnosis and it has been proposed that two major groups of tumours exist that develop via different molecular pathways. Low-grade, non-invasive papillary tumours recur frequently, but patients with these tumours do not often suffer progression of disease to muscle invasion. In contrast, tumours that are invading muscle at diagnosis are aggressive and associated with significant mortality. Molecular studies have identified distinct genetic, epigenetic and expression changes in these groups. However, it is not yet clear whether there is direct progression of low-grade superficial tumours to become invasive (a Jeckell and Hyde scenario) or whether in those patients who apparently progress from one form of the disease to the other, different tumour clones are involved and that the two tumour groups are mutually exclusive ('chalk and cheese'). If the latter is true, then attempts to identify molecular markers to predict progression of low-grade superficial bladder tumours may be fruitless. Similarly, it is not clear whether other subgroups of tumours exist that arise via different molecular pathways. There is now a large amount of molecular information about bladder cancer that facilitates examination of these possibilities. Some recent studies provide evidence for the existence of at least one further group of tumours, high-grade superficial papillary tumours, which may develop via a distinct molecular pathway. Patients with such tumours do show increased risk of disease progression and for these there may exist a real progression continuum from non-invasive to invasive. If this is the case, definition of the molecular signature of this pathway and improved understanding of the biological consequences of the events involved will be pivotal in disease management.

Entities:  

Mesh:

Year:  2005        PMID: 16352616     DOI: 10.1093/carcin/bgi310

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  88 in total

1.  Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Authors:  Willemien Beukers; Raju Kandimalla; Roy G Masius; Marcel Vermeij; Ries Kranse; Geert Jlh van Leenders; Ellen C Zwarthoff
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

2.  High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.

Authors:  Jung-Woo Choi; Younghye Kim; Ju-Han Lee; Young-Sik Kim
Journal:  Virchows Arch       Date:  2013-08-31       Impact factor: 4.064

3.  Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer.

Authors:  Omkara L Veeranki; Arup Bhattacharya; Li Tang; James R Marshall; Yuesheng Zhang
Journal:  Curr Pharmacol Rep       Date:  2015-08

4.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

Review 5.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

7.  Up-regulation of microRNA in bladder tumor tissue is not common.

Authors:  Gang Wang; Honghe Zhang; Huadong He; Wenjuan Tong; Bin Wang; Guodong Liao; Zhaodian Chen; Caigan Du
Journal:  Int Urol Nephrol       Date:  2009-05-28       Impact factor: 2.370

8.  Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.

Authors:  Zhongbo Liu; Xia Xu; Xuesen Li; Shuman Liu; Anne R Simoneau; Feng He; Xue-Ru Wu; Xiaolin Zi
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-11

9.  A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.

Authors:  Lambertus A Kiemeney; Patrick Sulem; Soren Besenbacher; Sita H Vermeulen; Asgeir Sigurdsson; Gudmar Thorleifsson; Daniel F Gudbjartsson; Simon N Stacey; Julius Gudmundsson; Carlo Zanon; Jelena Kostic; Gisli Masson; Hjordis Bjarnason; Stefan T Palsson; Oskar B Skarphedinsson; Sigurjon A Gudjonsson; J Alfred Witjes; Anne J Grotenhuis; Gerald W Verhaegh; D Timothy Bishop; Sei Chung Sak; Ananya Choudhury; Faye Elliott; Jennifer H Barrett; Carolyn D Hurst; Petra J de Verdier; Charlotta Ryk; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Paolo Vineis; Silvia Polidoro; Simonetta Guarrera; Carlotta Sacerdote; Marcello Campagna; Donatella Placidi; Cecilia Arici; Maurice P Zeegers; Eliane Kellen; Berta Saez Gutierrez; José I Sanz-Velez; Manuel Sanchez-Zalabardo; Gabriel Valdivia; Maria D Garcia-Prats; Jan G Hengstler; Meinolf Blaszkewicz; Holger Dietrich; Roel A Ophoff; Leonard H van den Berg; Kristin Alexiusdottir; Kristleifur Kristjansson; Gudmundur Geirsson; Sigfus Nikulasson; Vigdis Petursdottir; Augustine Kong; Thorgeir Thorgeirsson; N Aydin Mungan; Annika Lindblom; Michael A van Es; Stefano Porru; Frank Buntinx; Klaus Golka; José I Mayordomo; Rajiv Kumar; Giuseppe Matullo; Gunnar Steineck; Anne E Kiltie; Katja K H Aben; Eirikur Jonsson; Unnur Thorsteinsdottir; Margaret A Knowles; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2010-03-28       Impact factor: 38.330

10.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.